USD 0.03
(20.42%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | -250 Thousand USD | 87.97% |
2022 | -2.07 Million USD | -90.04% |
2021 | -1.09 Million USD | 7.13% |
2020 | -1.17 Million USD | 7.39% |
2019 | -1.27 Million USD | -143.21% |
2018 | -523 Thousand USD | 7.92% |
2017 | -568 Thousand USD | 40.21% |
2016 | -950 Thousand USD | -219.78% |
2015 | 793.15 Thousand USD | 136.65% |
2014 | -2.16 Million USD | -28.21% |
2013 | -1.68 Million USD | -20.66% |
2012 | -1.39 Million USD | -7561.33% |
2011 | 18.75 Thousand USD | 0.0% |
2010 | - USD | 0.0% |
2009 | - USD | 100.0% |
2008 | -950.00 USD | 0.0% |
2007 | - USD | 0.0% |
2006 | - USD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 FY | -250 Thousand USD | 87.97% |
2023 Q2 | - USD | 100.0% |
2023 Q1 | -245 Thousand USD | 33.6% |
2023 Q3 | - USD | 0.0% |
2023 Q4 | 245 Thousand USD | 0.0% |
2022 Q3 | - USD | 100.0% |
2022 Q1 | - USD | 0.0% |
2022 FY | -2.07 Million USD | -90.04% |
2022 Q4 | -369 Thousand USD | 0.0% |
2022 Q2 | -506 Thousand USD | 0.0% |
2021 Q4 | - USD | 0.0% |
2021 Q3 | - USD | 0.0% |
2021 Q1 | - USD | 0.0% |
2021 Q2 | - USD | 0.0% |
2021 FY | -1.09 Million USD | 7.13% |
2020 Q2 | - USD | 0.0% |
2020 FY | -1.17 Million USD | 7.39% |
2020 Q1 | - USD | -100.0% |
2020 Q3 | - USD | 0.0% |
2020 Q4 | - USD | 0.0% |
2019 Q3 | -72.86 Thousand USD | -3.29% |
2019 FY | -1.27 Million USD | -143.21% |
2019 Q4 | 143.41 Thousand USD | 296.82% |
2019 Q2 | -70.54 Thousand USD | 0.0% |
2019 Q1 | - USD | -100.0% |
2018 Q3 | -99 Thousand USD | 17.5% |
2018 Q4 | 713 Thousand USD | 820.2% |
2018 FY | -523 Thousand USD | 7.92% |
2018 Q1 | -193 Thousand USD | -124.97% |
2018 Q2 | -120 Thousand USD | 37.82% |
2017 Q2 | -216 Thousand USD | 1.37% |
2017 FY | -568 Thousand USD | 40.21% |
2017 Q4 | 773 Thousand USD | 6541.67% |
2017 Q3 | -12 Thousand USD | 94.44% |
2017 Q1 | -219 Thousand USD | -116.29% |
2016 FY | -950 Thousand USD | -219.78% |
2016 Q4 | 1.34 Million USD | 576.6% |
2016 Q2 | -302 Thousand USD | -66.85% |
2016 Q1 | -181 Thousand USD | -180.4% |
2016 Q3 | -282 Thousand USD | 6.62% |
2015 Q4 | 225.11 Thousand USD | -49.98% |
2015 Q2 | 96.55 Thousand USD | 127.08% |
2015 Q1 | -356.57 Thousand USD | 9.17% |
2015 Q3 | 450.06 Thousand USD | 366.14% |
2015 FY | 793.15 Thousand USD | 136.65% |
2014 Q2 | -641.57 Thousand USD | -5232.57% |
2014 Q4 | -392.57 Thousand USD | 26.43% |
2014 Q3 | -533.57 Thousand USD | 16.83% |
2014 FY | -2.16 Million USD | -28.21% |
2014 Q1 | 12.5 Thousand USD | 0.0% |
2013 FY | -1.68 Million USD | -20.66% |
2013 Q2 | 12.5 Thousand USD | 0.0% |
2013 Q3 | 12.5 Thousand USD | 0.0% |
2013 Q4 | 12.5 Thousand USD | 0.0% |
2013 Q1 | 12.5 Thousand USD | 0.0% |
2012 Q4 | 12.5 Thousand USD | 0.0% |
2012 FY | -1.39 Million USD | -7561.33% |
2012 Q3 | 12.5 Thousand USD | 0.0% |
2012 Q2 | 12.5 Thousand USD | 0.0% |
2012 Q1 | 12.5 Thousand USD | 0.0% |
2011 Q4 | 12.5 Thousand USD | 100.0% |
2011 Q1 | - USD | 0.0% |
2011 FY | 18.75 Thousand USD | 0.0% |
2011 Q3 | 6250.00 USD | 0.0% |
2011 Q2 | - USD | 0.0% |
2010 Q1 | - USD | 0.0% |
2010 Q2 | - USD | 0.0% |
2010 Q3 | - USD | 0.0% |
2010 Q4 | - USD | 0.0% |
2010 FY | - USD | 0.0% |
2009 FY | - USD | 100.0% |
2009 Q1 | - USD | 100.0% |
2009 Q4 | - USD | 100.0% |
2009 Q3 | -800.00 USD | -166.67% |
2009 Q2 | -300.00 USD | 0.0% |
2008 Q2 | - USD | 0.0% |
2008 Q3 | - USD | 0.0% |
2008 Q4 | -950.00 USD | 0.0% |
2008 FY | -950.00 USD | 0.0% |
2008 Q1 | - USD | 0.0% |
2007 Q4 | - USD | 0.0% |
2007 Q1 | - USD | 0.0% |
2007 Q2 | - USD | 0.0% |
2007 FY | - USD | 0.0% |
2007 Q3 | - USD | 0.0% |
2006 FY | - USD | 0.0% |
2006 Q4 | - USD | 0.0% |
2006 Q3 | - USD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
America Great Health | 168.58 Thousand USD | 248.291% |
Aridis Pharmaceuticals, Inc. | - USD | Infinity% |
Biora Therapeutics, Inc. | -551 Thousand USD | 54.628% |
Bio-Path Holdings, Inc. | -178 Thousand USD | -40.449% |
Better Therapeutics, Inc. | -2.72 Million USD | 90.839% |
Calithera Biosciences, Inc. | -1.38 Million USD | 81.949% |
Comera Life Sciences Holdings, Inc. | 422.71 Thousand USD | 159.142% |
Gene Biotherapeutics, Inc. | - USD | Infinity% |
eFFECTOR Therapeutics, Inc. | -22.91 Million USD | 98.909% |
Eloxx Pharmaceuticals, Inc. | - USD | Infinity% |
Evelo Biosciences, Inc. | - USD | Infinity% |
Evolutionary Genomics, Inc. | -1.02 Million USD | 75.526% |
Finch Therapeutics Group, Inc. | -7.09 Million USD | 96.475% |
Galera Therapeutics, Inc. | -259 Thousand USD | 3.475% |
Innovation1 Biotech Inc. | -52.69 Thousand USD | -374.401% |
Kiromic BioPharma, Inc. | -2.79 Million USD | 91.058% |
Molecular Templates, Inc. | 50.39 Million USD | 100.496% |
Navidea Biopharmaceuticals, Inc. | -119.29 Thousand USD | -109.565% |
NexImmune, Inc. | -1.02 Million USD | 75.609% |
Orgenesis Inc. | -5.72 Million USD | 95.633% |
Panbela Therapeutics, Inc. | -25.64 Million USD | 99.025% |
Point of Care Nano-Technology, Inc. | -4601.00 USD | -5333.601% |
PaxMedica, Inc. Common Stock | - USD | Infinity% |
Scopus BioPharma Inc. | - USD | Infinity% |
Sorrento Therapeutics, Inc. | 29.38 Million USD | 100.851% |
Statera Biopharma, Inc. | -488.31 Thousand USD | 48.803% |
TRACON Pharmaceuticals, Inc. | -232 Thousand USD | -7.759% |
Trevena, Inc. | 1.45 Million USD | 117.182% |
Vaxxinity, Inc. | -2.23 Million USD | 88.809% |
Vaccinex, Inc. | -16 Million USD | 98.438% |
Vicapsys Life Sciences, Inc. | - USD | Infinity% |
Viracta Therapeutics, Inc. | -492 Thousand USD | 49.187% |
ZIVO Bioscience, Inc. | 11.61 Thousand USD | 2253.316% |